Nobody's watching the post-quantum hardware mandate. $420M cash, $3.5 stock. $LAES

AI SUMMARY — Lantheus Medical Technologies (LAES) is trading at $3.50 with $420M cash despite having mandated post-quantum cryptography hardware that could unlock significant value. The key risks include execution delays on quantum-resistant technology adoption, competitive threats from larger players, and regulatory timelines that may not align with current stock pricing.